1 January 2025 in The Anatolian Journal of Cardiology
With the increasing incidence of cancer among the adult population, radiotherapy (RT) is frequently used as a critical component in the treatment of various cancer types. Due to the nature of ionizing radiation, damage usually occurs within the tissues in anatomical neighborhood with the primary tumor localization. Dapagliflozin (DAPA), originally developed as an oral anti-diabetic medication, has been shown to have potent cardioprotective effects in the DAPA-HF trial. The cardioprotective effects of DAPA against RT induced cardiac cellular damage were investigated in this study. A total of 40 male Wistar albino rats were obtained and were subjected to a 10-day pretreatment period to accommodate laboratory settings. Afterwards, the rats were divided into 4 groups consisting of 10 each (control = 10, DAPA = 10, RT = 10, RT + DAPA = 10). Meanwhile, the RT and RT + DAPA groups received a single dose of 20 Gray (Gy) x-ray to 4 × 4 cm area at 0.60 Gy/min, and DAPA and RT + DAPA groups were gavaged daily with 10 mg/kg DAPA. In the second week of the study, rats were examined by echocardiography and electrocardiogram. Furthermore, histopathological method was used to evaluate the level of cardiotoxicity. The ejection fraction value decreased by 17.3% lower in the DAPA + RT group compared with the RT group (P < .001). In addition, corrected QT interval prolongation and QRS widening were 11.5% and 17.4% higher in the RT group compared with the DAPA + RT group, respectively (P < .001 for both values). While sarcomyolysis, inflammatory cell infiltration, and necrotic changes were found to be severe in the RT group, the DAPA + RT group had 68% less sarcomyolysis, 64% less inflammatory cell infiltration, and 55% less necrosis (P < .001 for all values). The protective effects of DAPA against left ventricular remodeling and dysfunction in RT-induced cardiomyopathy model were observed in this study.
16 January 2026 in Genel Tıp Dergisi
Aim: This study investigated whether the CHA2DS2-VASc score is an independent predictor of high thrombus burden and mortality in patients presenting with acute coronary syndrome (ACS) and Coronavirus Ddisease (COVID-19).Materials and Methods: Patients with acute coronary syndrome (ACS) and COVID-19 (n = 76) were included in the study. They were categorized into low thrombus burden (LTB; grades 1–3) and high thrombus burden (HTB; grades 4 and 5) groups according to the final thrombus score. The CHA2DS2-VAScscores were then compared between the two groups.Results: Post-procedural HTB developed in 50 patients (65.7%). The neutrophil-to-lymphocyte ratio (6.00 ± 3.73 vs. 11.45 ± 10.6; P < 0.05), creatinine (0.84 ± 0.22 vs. 1.51 ± 0.92 mg/dL; P < 0.05), blood urea nitrogen (42.27 ± 12.6 vs. 62.27 ± 48.2 mg/dL; P < 0.05), potassium (4.06 ± 0.35 vs. 4.51 ± 0.49 mEq/L; P < 0.05), ferritin (286 ± 55.2 vs. 730 ± 96.8 ng/mL; P < 0.05), interleukin-6 (18.12 ± 7.14 vs. 186.66 ± 56.8 pg/mL; P < 0.05), lactate dehydrogenase (425.7 ± 31.2 vs. 1002.7 ± 173.4 U/L; P < 0.05), and CHA2DS2-VASc score (2.84 ± 1.27 vs. 4.08 ± 1.61; P < 0.05) were significantly higher in the HTB group. Mortality [3 (11.5%) vs 23 (46.0%), P<0.05)] and CHA2DS2-VASc score (2.84 ± 1.27 vs 4.08 ± 1.61, P<0.05) were higher in the HTB group (Table 1).Conclusions: In this study, the easily calculated CHA2DS2-VASc score was an independent predictor of HTB in patients with COVID-19 presenting with ACS. In addition, it predicted mortality in the same patient group.
12 March 2025 in Eskisehir Medical Journal, Eskisehir City Hospital
Introduction: Atrioventricular nodal reentrant tachycardia (AVNRT) is one of the most common types of narrow QRS complex supraventricular tachycardias. Catheter ablation is considered one of the most effective treatment methods for AVNRT due to its high success rates and low complication risks. However, it is crucial to evaluate the changes in the atrioventricular conduction system following ablation. In this study, electrocardiographic changes in patients who underwent AVNRT ablation were analyzed. Methods: A total of 148 patients who were presented with palpitations and were diagnosed with AVNRT through an electrophysiological study between January 2023 and December 2024 were included in the study. The minimum required sample size to detect a 1 msn difference between the two groups was calculated as at least 44 individuals with 90% power and a 0.05 Type I error using the open-source program R 3.0.1. Descriptive statistics of the data included mean, standard deviation, ratio, and frequency values. The Kolmogorov-Smirnov test was used to assess the normality of continuous variable distributions. The McNemar test was used for the analysis of dependent variables. The Student's t-test was used for the analysis of parametric data, while the Mann-Whitney U test was used for nonparametric data. Statistical significance was defined as p < 0.05. Results: After ablation, heart rate increased significantly, while the QRS duration also showed a statistically significant prolongation. A slight but significant prolongation was observed in the PR interval as well. However, no significant change was detected in the corrected QT interval. Conclusions: Following AVNRT ablation, slight but significant changes were observed in heart rate, QRS duration, and PR interval. These changes are thought to be associated with the modification of the slow pathway of the atrioventricular node. The absence of a significant change in the QTc interval suggests that ablation does not have a negative impact on ventricular repolarization. These electrocardiographic changes following successful AVNRT ablation may serve as potential predictors of success, particularly in patients without well-defined endpoints.